RGLS
Income statement / Annual
Last year (2024), Regulus Therapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Regulus Therapeutics Inc.'s net income was -$46.36 M.
See Regulus Therapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$10.01 M |
$6.83 M |
$72.00 K |
$72.00 K |
$1.19 M |
$20.76 M |
| Cost of Revenue |
$0.00
|
$21.15 M
|
$122.00 K
|
$459.00 K
|
$15.35 K
|
$12.35 K
|
$33.98 M
|
$54.59 M
|
$64.31 M
|
$56.39 M
|
| Gross Profit |
$0.00
|
-$21.15 M
|
-$122.00 K
|
-$459.00 K
|
$9.99 M
|
$6.82 M
|
-$33.90 M
|
-$54.52 M
|
-$63.11 M
|
-$35.63 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
1
|
1
|
-470.88
|
-757.21
|
-52.86
|
-1.72
|
| Research and Development Expenses |
$35.37 M
|
$21.01 M
|
$18.41 M
|
$17.79 M
|
$15.35 M
|
$12.35 M
|
$33.98 M
|
$53.19 M
|
$64.31 M
|
$56.39 M
|
| General & Administrative Expenses |
$14.67 M
|
$9.96 M
|
$9.83 M
|
$10.02 M
|
$8.81 M
|
$11.32 M
|
$12.86 M
|
$17.01 M
|
$18.39 M
|
$19.13 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$14.67 M
|
$9.96 M
|
$9.83 M
|
$10.02 M
|
$8.81 M
|
$11.32 M
|
$12.86 M
|
$17.01 M
|
$18.39 M
|
$19.13 M
|
| Other Expenses |
$0.00
|
-$21.01 M
|
-$83.00 K
|
$9.00 K
|
-$1.58 M
|
-$1.76 M
|
-$1.88 M
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$50.04 M
|
$9.96 M
|
$28.24 M
|
$27.82 M
|
$24.16 M
|
$23.67 M
|
$46.84 M
|
$70.20 M
|
$82.70 M
|
$75.52 M
|
| Cost And Expenses |
$50.04 M
|
$31.11 M
|
$28.24 M
|
$27.82 M
|
$24.16 M
|
$23.67 M
|
$46.84 M
|
$70.20 M
|
$82.70 M
|
$75.52 M
|
| Interest Income |
$3.84 M
|
$1.68 M
|
$605.00 K
|
$864.00 K
|
$233.00 K
|
$374.00 K
|
$459.00 K
|
$752.00 K
|
$844.00 K
|
$855.00 K
|
| Interest Expense |
$158.00 K
|
$604.00 K
|
$688.00 K
|
$855.00 K
|
$1.81 M
|
$2.13 M
|
$2.34 M
|
$2.72 M
|
$1.18 M
|
$52.00 K
|
| Depreciation & Amortization |
$347.00 K
|
$227.00 K
|
$122.00 K
|
$459.00 K
|
$467.00 K
|
$931.00 K
|
$2.26 M
|
$2.52 M
|
$2.28 M
|
$1.59 M
|
| EBITDA |
-$45.85 M |
-$30.88 M |
-$28.12 M |
-$27.36 M |
-$13.46 M |
-$15.53 M |
-$44.04 M |
-$66.86 M |
-$78.38 M |
-$54.12 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
-1.34
|
-2.27
|
-611.69
|
-928.54
|
-65.65
|
-2.61
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
-1.41
|
-2.46
|
-649.49
|
-974.04
|
-68.26
|
-2.64
|
| Total Other Income/Expenses Net |
$3.68 M
|
$1.07 M
|
-$83.00 K
|
$9.00 K
|
-$1.58 M
|
-$1.76 M
|
-$1.88 M
|
-$1.97 M
|
-$338.00 K
|
-$1.01 M
|
| Income Before Tax |
-$46.36 M
|
-$30.04 M
|
-$28.32 M
|
-$27.81 M
|
-$15.73 M
|
-$18.59 M
|
-$48.65 M
|
-$72.10 M
|
-$81.84 M
|
-$55.77 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
-1.57
|
-2.72
|
-675.65
|
-1001.42
|
-68.54
|
-2.69
|
| Income Tax Expense |
$1.00 K
|
$1.00 K
|
$1.00 K
|
$1.00 K
|
-$467.00 K
|
$1.00 K
|
$62.00 K
|
-$197.00 K
|
-$4.00 K
|
-$18.00 K
|
| Net Income |
-$46.36 M
|
-$30.04 M
|
-$28.32 M
|
-$27.81 M
|
-$15.26 M
|
-$18.59 M
|
-$48.71 M
|
-$71.91 M
|
-$81.84 M
|
-$55.75 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
-1.53
|
-2.72
|
-676.51
|
-998.68
|
-68.54
|
-2.69
|
| EPS |
-0.82 |
-1.58 |
-1.86 |
-3.24 |
-4.36 |
-10.77 |
-55.87 |
-114.7 |
-185.94 |
-130.12 |
| EPS Diluted |
-0.82 |
-1.58 |
-1.86 |
-3.24 |
-4.36 |
-10.77 |
-55.87 |
-114.7 |
-185.94 |
-130.12 |
| Weighted Average Shares Out |
$56.35 M
|
$18.96 M
|
$15.26 M
|
$8.57 M
|
$3.50 M
|
$1.73 M
|
$871.86 K
|
$626.92 K
|
$440.11 K
|
$428.43 K
|
| Weighted Average Shares Out Diluted |
$56.35 M
|
$18.96 M
|
$15.26 M
|
$8.57 M
|
$3.50 M
|
$1.73 M
|
$871.86 K
|
$626.92 K
|
$440.11 K
|
$428.43 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
